Navigation Links
Inclinix Releases Next Generation Critical Population Research(R) (CPR) for Clinical Trial Investigator Site Selection and Patient Recruitment

WILMINGTON, N.C., Jan. 13 /PRNewswire/ -- Inclinix, Inc., a clinical trial enrollment solutions provider, announces the release of its next generation Critical Population Research(R) (CPR) system. A proprietary technology that integrates numerous public and private databases, CPR analyzes each investigator site for multiple criteria to identify the optimal sites for clinical trials. The CPR database has been expanded to include profiles on 40,000 additional investigators, now totaling over 100,000, including thousands of international investigators. This international capacity provides sponsors with a global analysis of prospective sites.

Critical Population Research identifies where patients with a specific condition are concentrated by providing color-coded maps of disease prevalence from national to ZIP code level. These maps identify clusters of sites that maximize media budgets and even provide visual insight into geographic barriers to clinical trial participation, such as availability of public transportation or parking. Inclinix's Media Optimizer uses this aspect of CPR as its foundation, implementing only the most effective and cost-efficient patient outreach for each site. This process, complemented by the extensive CPR investigator database, provides a powerful dataset for site selection and patient recruitment.

"The clinical trials industry has repeatedly identified site initiation as a primary cause of delays," explains J. Tobin Geatz, Inclinix President and CEO. "Our enhanced CPR technology offers our clients a proven, scientific solution to investigator site selection. By initiating only the most qualified investigators who have access to the right patients, trials will enroll - and ultimately complete - faster and at less cost."

In a three-year retrospective analysis of multiple trials, Inclinix found that investigators located in CPR "hot zones" (areas of high disease prevalence) enrolled at a rate nearly three times faster than those located in "cold zones" (areas of low disease prevalence). This data-driven approach to site selection results in identification of the most qualified investigators, leading to faster, more effective patient recruitment and trial completion.

About Inclinix

Inclinix, Inc. specializes in customized Phase I-IV clinical trial enrollment solutions that deliver productive investigator sites and qualified patients for the pharmaceutical, biotech and medical device industry. Clients benefit from ten years of experience in multiple therapeutic areas, as well as leading edge technologies that meet the challenge of clinical development from feasibility through compliance.

For more information, visit

SOURCE Inclinix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Inclinix Announces New Patent for Expert System Platform
2. Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials
3. Eularis Releases First-Ever Study on ROI of Pre-Launch Named Patient Programmes
4. Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
5. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
6. CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence
7. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
8. Immunosyn Releases Wound Healing Photographs From the First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
9. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
10. Immunosyn Corporation Releases SF-1019 Study Results
11. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
Post Your Comments:
(Date:11/26/2015)... STOCKHOLM , November 26, 2015 ... the potential to use SyMRI to find optimal contrast weighting ... brain tumor metastases, and has signed a research agreement with ... at the hospital. Using SyMRI, it is possible to generate ... parameter settings after the patient has left, thus making it ...
(Date:11/26/2015)... 2015 ) ... "2016 Future Horizons and Growth Strategies in ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> ) has announced ... Horizons and Growth Strategies in the French ...
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 Research ... of the "Advanced Wound Care Market by Type ... Ulcers), End User (In-Patient Facility, Out-Patient Facility), and Geography ... offering. --> --> ... the description, definition and forecast of the global advanced ...
Breaking Medicine Technology:
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... a safe and convenient way to dispense prescription medications at home, so he ... effective way to monitor and dispense prescription medications. In doing so, it could ...
(Date:11/27/2015)... ... , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of ... than 3.7 billion people under the age of 50 – or 67% of the population ... global estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... an innovative online platform for mental health and wellness consultation, has collaborated with ... partnership will bridge the knowledge gap experienced by parents and bring advice from ...
(Date:11/27/2015)... ... 27, 2015 , ... Indosoft Inc., developer and distributor of ... 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. , Making ... with a version of Asterisk that will receive not only security fixes, but ...
(Date:11/26/2015)... ... ... The Catalent Applied Drug Delivery Institute today announced a ... selection in early phase drug development. The first of these is to be ... UK’s emerging life sciences companies, corporate partners, and investors, at Milton Park, Oxford, ...
Breaking Medicine News(10 mins):